Drug Approval, Reimbursement Are “Bookends” Of Innovation – Rep. Eshoo
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approval of innovative products must be matched with an efficient and equitable Medicare reimbursement process, the Democratic congresswoman tells the California Healthcare Institute. Increased financial pressures on government programs necessitate advocacy about the value of innovation, she says.